Literature DB >> 32188606

Symptomatic hyponatremia: a rare but reversible adverse reaction of lubiprostone.

Tsuneo Takenaka1, Mikio Zeniya2, Soichiro Miura2, Takahiro Amano2.   

Abstract

Several intestinal secretagogues became available for the patients with irritable bowel syndrome. We report a case of symptomatic hyponatremia after lubiprostone ingestion. A male patient was visiting our office to manage chronic kidney disease. He suffered chronic hepatitis (type C), which was successfully treated with asunaprevir and daclatasvir. He took lubiprostone due to constipation, and then watery diarrhoea was frequently developed. Next morning, he came to our hospital due to consciousness disturbance. Physical examination showed dehydration and laboratory data exhibited hyponatremia (110 mEq/L). Subsequent treatment against hypovolemic hyponatremia recovered his consciousness without any sequels. This case suggests that intestinal secretagogues can accompany severe electrolyte disturbance. Potential mechanisms for hyponatremia were discussed. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chronic renal failure; drugs and medicines; hepatitis C; neurology

Mesh:

Substances:

Year:  2020        PMID: 32188606      PMCID: PMC7078685          DOI: 10.1136/bcr-2019-232438

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  New treatment options for chronic constipation: mechanisms, efficacy and safety.

Authors:  Michael Camilleri
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

2.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Koichi Takaguchi; Toru Ishikawa; Kunihiko Tsuji; Mikio Zeniya; Etsuko Iio; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2016-02-12       Impact factor: 7.527

3.  A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

Authors:  Fumiaki Obata; Taichi Murakami; Junko Miyagi; Sayo Ueda; Taizo Inagaki; Masanori Minato; Hiroyuki Ono; Kenji Nishimura; Eriko Shibata; Masanori Tamaki; Sakiya Yoshimoto; Fumi Kishi; Seiji Kishi; Motokazu Matsuura; Kojiro Nagai; Hideharu Abe; Toshio Doi
Journal:  CEN Case Rep       Date:  2016-11-21

Review 4.  Pathogenesis of water and sodium retention in cirrhosis.

Authors:  P Y Martin; R W Schrier
Journal:  Kidney Int Suppl       Date:  1997-06       Impact factor: 10.545

5.  Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD.

Authors:  Eikan Mishima; Shinji Fukuda; Hisato Shima; Akiyoshi Hirayama; Yasutoshi Akiyama; Yoichi Takeuchi; Noriko N Fukuda; Takehiro Suzuki; Chitose Suzuki; Akinori Yuri; Koichi Kikuchi; Yoshihisa Tomioka; Sadayoshi Ito; Tomoyoshi Soga; Takaaki Abe
Journal:  J Am Soc Nephrol       Date:  2014-12-18       Impact factor: 10.121

6.  Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Authors:  Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson
Journal:  Am J Med       Date:  2013-10       Impact factor: 4.965

7.  C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

Authors:  Iain C Macdougall; Rowan Walker; Robert Provenzano; Fernando de Alvaro; Harold R Locay; Paul C Nader; Francesco Locatelli; Frank C Dougherty; Ulrich Beyer
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.